Flibanserin

GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Flibanserin is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2015. Its mechanism of action is classified as P-Glycoprotein Inhibitors. DrugCentral lists 9 molecular targets, including HTR1A, DRD4 and Htr1a. Recorded indications include Lack or loss of sexual desire.

• Approval status: ofp (first approved 2015 by the FDA).
• Mechanism of action: P-Glycoprotein Inhibitors.
• Molecular targets: HTR1A, DRD4, Htr1a and HTR2A (9 listed in DrugCentral).
• Indications: Lack or loss of sexual desire.
• ATC code: G02CX02 (Other gynecologicals).
• Molecular formula: C20H21F3N4O; molecular weight 390.41 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Lack or loss of sexual desire

Contraindications (1)

• Decreased liver function

Mechanism & targets

• Mechanism of action (MoA): P-Glycoprotein Inhibitors

Molecular targets (9)

Target	Gene	Action	Activity
5-hydroxytryptamine receptor 1A	HTR1A	agonist	Ki 9.00
D(4) dopamine receptor	DRD4	antagonist	Ki 8.40
5-hydroxytryptamine receptor 1A	Htr1a	unknown	Ki 7.93
5-hydroxytryptamine receptor 2A	HTR2A	antagonist	Ki 7.31
5-hydroxytryptamine receptor 2C	HTR2C	antagonist	Ki 7.05
5-hydroxytryptamine receptor 2B	HTR2B	antagonist	Ki 7.05
D(2) dopamine receptor	DRD2	unknown	Ki 6.52
D(3) dopamine receptor	DRD3	unknown	Ki 6.44
5-hydroxytryptamine receptor 5A	HTR5A	unknown	Ki 6.09

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2015-08-18	FDA	—	SPROUT PHARMACEUTICALS INC

ATC classification

ATC code	Therapeutic hierarchy
G02CX02	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Other gynecologicals

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label: CYP2C9, CYP2D6 · Informative PGx
• FDA label: CYP2C19 · Actionable PGx
• HCSC label: CYP2C19 · Actionable PGx
• HCSC label: CYP2C9, CYP2D6 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Accidental exposure to product by child	125.7
Therapeutic response unexpected	85.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Flibanserin is on its molecule page.

• Molecular formula: C₂₀H₂₁F₃N₄O
• Molecular weight: 390.41 g/mol
• CAS number: 167933-07-5
• InChIKey: PPRRDFIXUUSXRA-UHFFFAOYSA-N
• PubChem CID: 6918248

FC(F)(F)C1=CC=CC(=C1)N1CCN(CCN2C(=O)NC3=CC=CC=C23)CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Flibanserin used for?

DrugCentral lists the following indications for Flibanserin: Lack or loss of sexual desire.

How does Flibanserin work?

Flibanserin is classified as P-Glycoprotein Inhibitors; its molecular targets in DrugCentral include HTR1A (agonist), DRD4 (antagonist), Htr1a and HTR2A (antagonist).

When was Flibanserin first approved?

Flibanserin was first approved by the FDA in 2015.

What is the chemical formula of Flibanserin?

Flibanserin has the molecular formula C20H21F3N4O and a molecular weight of 390.41 g/mol.

Sources

• DrugCentral drug card 5022 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL231068 — compound record and bioactivity
• PubChem CID 6918248 — chemical identifiers
• DrugBank DB04908 — drug record
• FDA UNII 37JK4STR6Z — substance identity
• DailyMed: FDA labels for Flibanserin — current prescribing information (label search)
• UniProt P08908 (HTR1A) — target protein
• UniProt P21917 (DRD4) — target protein
• UniProt P28223 (HTR2A) — target protein
• UniProt P28335 (HTR2C) — target protein
• UniProt P41595 (HTR2B) — target protein
• UniProt P14416 (DRD2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.